SymBio Pharmaceuticals Limited was listed on the Osaka Securities Exchange JASDAQ Growth Market on October 20, 2011, an enormous achievement only made possible thanks to the unyielding support and guidance that we have received from our stakeholders. I would like to take this opportunity to express my deepest gratitude to you all.
Since its establishment in March, 2005, SymBio has pursued new drug development with the underlying principle of addressing underserved medical needs in the oncology and hematology space in Japan and other parts of Asia Pacific to create value for our stakeholders. The Company’s corporate vision and goals are interwoven with those of patients, physicians, investors and our peers in the pharmaceutical industry. Pivotal events in our relatively short corporate history, such as the granting of marketing approval of TREAKISYM® in Japan on October 27, 2010, and now IPO with approval from the Osaka Securities Exchange, continue to define and strengthen the Company’s financial base as well as operating base, leading to further expansion of our pipeline. As a public company, we will embark on further expansion of our business as we deliver new drugs and hope to patients in need while, in parallel, meeting and surpassing the expectations of our stakeholders.
SymBio’s board directors and employees are fully committed, embodying our corporate social responsibility and continued contribution to society as a public company, the cornerstone of earning public trust and bringing this corporate enterprise one step closer to meeting your expectations.
President and CEO